Mp69-07 Urologic Complications of Sodium-Glucose Co-Transporter-2 (Sglt-2) Inhibitors Differ Between Diabetic Men and Women

You have accessJournal of UrologyInfections/Inflammation/Cystic Disease of the Genitourinary Tract: Kidney & Bladder I (MP69)1 May 2024MP69-07 UROLOGIC COMPLICATIONS OF SODIUM-GLUCOSE CO-TRANSPORTER-2 (SGLT-2) INHIBITORS DIFFER BETWEEN DIABETIC MEN AND WOMEN Bradley Roth, Prajit Khooblall, Andrew Shumaker, Raevti Bole, Bradley Gill, and Petar Bajic Bradley RothBradley Roth , Prajit KhooblallPrajit Khooblall , Andrew ShumakerAndrew Shumaker , Raevti BoleRaevti Bole , Bradley GillBradley Gill , and Petar BajicPetar Bajic View All Author Informationhttps://doi.org/10.1097/01.JU.0001008892.86171.de.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are used for the treatment of hyperglycemia in patients with type 2 diabetes. Due to glucose filtration, SGLT-2 inhibitors may be associated with or cause increased lowery urinary tract symptoms (LUTS), such as overactive bladder (OAB). Given the anatomical potential for differing urologic outcomes, it is important to understand gender differences among patients prescribed these medications. In this retrospective study, we sought to characterize the differential frequency of new urologic visits and urologic diagnoses, such as urinary frequency, urgency, incontinence, urinary tract infection (UTI), and OAB between patients identifying as either male or female who had been recently started on SGLT-2 inhibitors. METHODS: We retrospectively reviewed records from our institution between 2014 to 2022 of patients who had been to a urology outpatient visit within 2 years and had been prescribed an SGLT-2 inhibitor. Patients were stratified based on male or female gender. Diagnoses were obtained via ICD-10 code. Data was collected and analyzed utilizing two-tailed t test and Chi-squared analyses. RESULTS: A total of n=23,114 patients were included in our analysis. Of these, n=9,997 identified as female, n=13,117 identified as male. Patients were matched on diabetic status after medication start (e.g. all had HbA1c values equal to or above 6.5). Table 1 lists all outcome frequencies. Of note, urologic appointments within 1 year of medication start (2.74% vs 2.13%, p=0.003), urinary frequency (1.25% vs 0.45%, p<0.0001), and urinary urgency (0.77% vs 0.45%, p=0.002) were all significantly higher in the male cohort. Meanwhile, recurrent UTI diagnosis (0.97% vs 0.58%, p<0.001) and UTI within 180 days (0.18% vs 0.03%, p<0.001) were significantly higher in females. OAB and urinary incontinence did not differ between groups. CONCLUSIONS: Our results demonstrate that SGLT-2 inhibitors were found to impact male and female gender patients differently. Male patients tended to have a higher frequency of LUTS, while females had more infectious sequalae. Based on these results, we suggest that caregivers should work collaboratively to monitor patients on SGLT-2 inhibitors, with attention tailored to patient risk factors including gender. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1120 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Bradley Roth More articles by this author Prajit Khooblall More articles by this author Andrew Shumaker More articles by this author Raevti Bole More articles by this author Bradley Gill More articles by this author Petar Bajic More articles by this author Expand All Advertisement PDF downloadLoading ...